After its drug Palifosfamide failed to show efficacy in a phase 3 sarcoma trial, shares of Ziopharm Oncology (TCRT -1.70%) fell through the floor, dropping by more than 66%. Do shareholders have any hope of a recovery? In this video, Motley Fool health-care analyst David Williamson takes us through what the cash situation looks like at Ziopharm, where the company will be shifting its focus next, and what, if any, hope remains.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.